| Summary: | 碩士 === 國立中興大學 === 環境工程學系所 === 105 === The primary goal of this study were to analyze the background levels of 17β-estradiol (E2)-derived quinone Albumin (Alb) adducts (E2-3,4-Q-2-Alb, E2-2,3-Q-4-Alb) in patients with breast carcinoma in situ and to investigate the disparity of these adducts with those in healthy controls (n=147) and patients with carcinoma (n=138). The specific aim was to correlate biomarkers of breast cancer used in preventive medicine with those applied in diagnosis and target therapy of breast cancer.
Results showed that the background levels of albumin (E2-3,4-Q-2-Alb, E2-2,3-Q-4-Alb) was 672 and 396 pmole/g in patients with breast carcinoma in situ, with median values at 614 (range187~1594) and 202 (range 80~963) (pmole/g), respectively. Additionally, levels of E2-3,4-Q-2-Alb and E2-2,3-Q-4-Alb in patients with breast carcinoma in situ were about 9 fold greater than those in healthy controls.
Further investigation indicated that mean values of E2-3, 4-Q-2-S-Alb and E2-2,3-Q-4-S-Alb were 614 and 311 (pmole/g) in invasive breast carcinoma patients, E2-3,4-Q-2-S-Alb and E2-2,3-Q-4-S-Alb in invasive breast carcinoma patients were approximately equal to those of patients with carcinoma in situ. In conclusion, E2-3,4-Q-2-S-Alb and E2-2,3-Q-4-S-Alb were not associated with clinical breast cancer diagnosis and treatment.
|
|---|
